Table 2.
Clinical characteristics of each cohort: ERSPC studies
| Göteborg Round 1 |
Göteborg Subsequent rounds |
Rotterdam Round 1 |
Rotterdam Subsequent rounds |
Tarn | |
|---|---|---|---|---|---|
| Number of patients | 740 | 1241 | 2895 | 1494 | 298 |
| Number of biopsies | 740 | 1241 | 2895 | 1494 | 298 |
|
Clinical characteristics |
|||||
| Age (years) | 61 (58, 64) | 63 (61, 67) | 66 (62, 70) | 67 (63, 71) | 64 (60, 67) |
| PSA (ng/mL) | 4.65 (3.68, 6.72) | 3.56 (3.17, 4.26) | 5.03 (3.93, 7.31) | 3.45 (2.94, 4.33) | 4.45 (3.53, 5.98) |
| Prostate volume2 (g) | 39 (30, 51) | 37 (30, 47) | 46 (35, 60) | 44 (35, 54) | NA |
| DRE result | |||||
| Normal | 614 (83%) | 1117 (90%) | 2137 (74%) | 1182 (79%) | 179 (60%) |
| Abnormal | 126 (17%) | 124 (10%) | 758 (26%) | 312 (21%) | 92 (31%) |
| Unknown | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 27 (9%) |
| Family history3 | |||||
| No | 0 (0%) | 0 (0%) | 1708 (59%) | 875 (59%) | 0 (0%) |
| Yes | 0 (0%) | 0 (0%) | 328 (11%) | 160 (11%) | 0 (0%) |
| Unknown | 740 (100%) | 1241 (100%) | 859 (30%) | 459 (31%) | 298 (100%) |
| African origin4 | |||||
| No | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Yes | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 740 (100%) | 1241 (100%) | 2895 (100%) | 1494 (100%) | 298 (100%) |
| Prior biopsy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Biopsy results | |||||
| Cancer | 192 (26%) | 322 (26%) | 800 (28%) | 388 (26%) | 96 (32%) |
| Biopsy Gleason grade | |||||
| ≤ 6 | 152 (79%) | 269 (84%) | 508 (63%) | 297 (77%) | 42 (44%) |
| 7 | 33 (17%) | 45 (14%) | 234 (29%) | 78 (20%) | 37 (39%) |
| ≥ 8 | 7 (4%) | 8 (2%) | 58 (7%) | 13 (3%) | 17 (18%) |
| Unknown | 0 (0%) | 0 (0%) | 6 (1%) | 0 (0%) | 3 (3%) |
| Clinical characteristics of each cohort: Other cohorts. | |||||
|---|---|---|---|---|---|
| SABOR | Cleveland Clinic1 | ProtecT | Tyrol1 | Durham VA | |
| Number of patients | 392 | 2631 | 7324 | 4199 | 1856 |
| Number of biopsies | 392 | 3307 | 7324 | 5656 | 2425 |
|
Clinical characteristics |
|||||
| Age (years) | 63 (58, 68) | 64 (58, 69) | 63 (59, 66) | 63 (57, 68) | 64 (59, 69) |
| PSA (ng/mL) | 3.42 (1.44, 5.40) | 5.75 (4.31, 8.50) | 4.35 (3.50, 6.20) | 4.21 (2.80, 6.79) | 5.17 (3.71, 8.27) |
| Prostate volume (g)2 | NA | 42 (30, 58) | NA | 35 (27, 46) | NA |
| DRE result | |||||
| Normal | 280 (71%) | 3103 (94%) | 0 (0%) | 5088 (90%) | 892 (37%) |
| Abnormal | 112 (29%) | 204 (6%) | 0 (0%) | 568 (10%) | 266 (11%) |
| Unknown | 0 (0%) | 0 (0%) | 7324 (100%) | 0 (0%) | 1267 (52%) |
| Family history3 | |||||
| No | 280 (71%) | 1708 (52%) | 5736 (78%) | 0 (0%) | 0 (0%) |
| Yes | 112 (29%) | 373 (11%) | 454 (6%) | 0 (0%) | 0 (0%) |
| Unknown | 0 (0%) | 1226 (37%) | 1134 (15%) | 5656 (100%) | 2425 (100%) |
| African origin4 | |||||
| No | 349 (89%) | 2836 (86%) | 6933 (95%) | 0 (0%) | 1221 (50%) |
| Yes | 43 (11%) | 425 (13%) | 34 (0%) | 0 (0%) | 1082 (45%) |
| Unknown | 0 (0%) | 46 (1%) | 357 (5%) | 5656 (100%) | 122 (5%) |
| Prior biopsy | 96 (24%) | 1093 (33%) | 0 (0%) | 1559 (28%) | 574 (24%) |
| Biopsy results | |||||
| Cancer | 133 (34%) | 1292 (39%) | 2570 (35%) | 1562 (28%) | 1148 (47%) |
| Biopsy Gleason grade | |||||
| ≤ 6 | 95 (71%) | 669 (52%) | 1703 (66%) | 911 (58%) | 606 (53%) |
| 7 | 28 (21%) | 478 (37%) | 729 (28%) | 319 (20%) | 387 (34%) |
| ≥ 8 | 10 (8%) | 145 (11%) | 138 (5%) | 332 (21%) | 155 (14%) |
| Unknown | 3 (2%) | 0 (0%) | 0 (0%) | 195 (12%) | 14 (1%) |
Data are given as median (quartiles) or frequency (proportion); NA: not available; DRE: digital rectal exam
1
Subjects may be represented more than once if they had more than 1 negative biopsy
2
Prostate volume was available for 733 Göteborg round 1; 967 Göteborg subsequent round; 2882 Rotterdam round 1; 1487 Rotterdam subsequent round; 2317 Cleveland Clinic; and 5178 Tyrol biopsies.
3
Family history of prostate cancer; when unknown, subjects were assumed to have no family history of prostate cancer
4
When unknown, subjects were assumed to be of non-African origin